RT Journal Article
SR Electronic
T1 High Dose Convalescent Plasma in COVID-19: Results from the Randomized Trial CAPSID
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.10.21256192
DO 10.1101/2021.05.10.21256192
A1 Körper, Sixten
A1 Weiss, Manfred
A1 Zickler, Daniel
A1 Wiesmann, Thomas
A1 Zacharowski, Kai
A1 M.Corman, Victor
A1 Grüner, Beate
A1 Ernst, Lucas
A1 Spieth, Peter
A1 Lepper, Philipp M.
A1 Bentz, Martin
A1 Zinn, Sebastian
A1 Paul, Gregor
A1 Kalbhenn, Johannes
A1 Dollinger, Matthias
A1 Rosenberger, Peter
A1 Kirschning, Thomas
A1 Thiele, Thomas
A1 Appl, Thomas
A1 Mayer, Benjamin
A1 Schmidt, Michael
A1 Drosten, Christian
A1 Wulf, Hinnerk
A1 Kruse, Jan Matthias
A1 Jungwirth, Bettina
A1 Seifried, Erhard
A1 Schrezenmeier, Hubert
A1 for the CAPSID Clinical Trial Group
YR 2021
UL http://medrxiv.org/content/early/2021/05/10/2021.05.10.21256192.abstract
AB Rationale COVID-19 convalescent plasma (CCP) has been considered a treatment option in COVID-19.Objectives To assess the efficacy of neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment.Methods Patients (n=105) were randomized 1:1 to either receive standard treatment and 3 units of CCP or standard treatment alone. Control group patients with progress on day 14 could cross over to the CCP group. Primary outcome was a dichotomous composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21. The trial is registered: clinicaltrials.gov #NCT04433910.Measurements and main results The primary outcome occurred in 43.4% of patients in the CCP and 32.7% in the control group (p=0.32). The median time to clinical improvement was 26 days (IQR 15-not reached (n.r.)) in the CCP group and 66 days (IQR 13-n.r.) in the control group (p=0.27). Median time to discharge from hospital was 31 days (IQR 16-n.r.) in the CCP and 51 days (IQR 20–n.r.) in the control group (p=0.24). In the subgroup that received a higher cumulative amount of neutralizing antibodies the primary outcome occurred in 56.0% (versus 32.1%), with a shorter interval to clinical improvement, shorter time to hospital discharge and better survival compared to the control group.Conclusion CCP added to standard treatment did not result in a significant difference in the primary and secondary outcomes. A pre-defined subgroup analysis showed a significant benefit for CCP among those who received a larger amount of neutralizing antibodies.Competing Interest StatementDr. Victor M Corman is named together with Euroimmun on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. The other authors do not declare a conflict of interest related to this trial.Clinical TrialEudraCT number 2020-001310-38 and NCT04433910Funding StatementThe clinical trial CAPSID is supported by the Bundesministerium fuer Gesundheit (German Federal Ministry of Health).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Federal Authority Paul-Ehrlich-Institute and by the Ethical Committee of the University of Ulm and the ethical committees of the participating hospitals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease send requests regarding availability of anonymized data to h.schrezenmeier{at}blutspende.de or s.koerper{at}blutspende.de.